Reed Jobs would rather talk about curing cancer than his last name
Reed Jobs, the son of Steve Jobs, is focused on curing cancer through his oncology-focused venture firm Yosemite. He launched Yosemite in 2023 to build biotech companies from scratch using a mix of philanthropy and venture capital. Yosemite has made significant progress, with a team of 17 and a cluster of blockbuster drugs losing patent protection, creating new opportunities for the firm.
- ▪Reed Jobs launched Yosemite in 2023 to build biotech companies from scratch, focusing on oncology.
- ▪Yosemite uses a mix of no-strings-attached philanthropy and old-fashioned venture capital to fund its companies.
- ▪The firm has a team of 17 and is targeting $350 million for its second fund.
TechCrunch files mainly under tech. We currently carry 594 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | TechCrunch |
| Canonical URL | https://techcrunch.com/2026/07/11/reed-jobs-would-rather-talk-about-curing-cancer-than-his-last-name/ |
| Publication time | Sun, 12 Jul 2026 00:16:06 +0000 |
| Retrieval time | 2026-07-12T00:44:49.903Z |
| Last seen | 2026-07-12T00:44:49.903Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | xia1Wcx_gCbc |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Reed Jobs is easy to like. He’s motormouthed, self-deprecating, prone to video-game analogies, and clearly loves his work. He doesn’t particularly want to discuss the fact that he is Steve Jobs’s son, but he’s not uptight about it, either. When our producer, Maggie, asked if he was on a MacBook for our video call Thursday morning, he didn’t miss a beat: “Are you kidding?” What he’d much rather talk about is Yosemite, the oncology-focused venture firm he launched in 2023 to, in part, build biotech companies from scratch, out of early academic research, using a mix of no-strings-attached philanthropy and old-fashioned venture capital.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TechCrunch.
Discussion
0 commentsMore from TechCrunch
